New Developments with Targeted Therapies for Patients with Advanced Renal Cell Cancer: Targeted Therapy for Clear-Cell RCC
| Title: | New Developments with Targeted Therapies for Patients with Advanced Renal Cell Cancer: Targeted Therapy for Clear-Cell RCC |
| Topic: | Oncology/ Hematology |
| Relevant Terms: | Dialysis/Renal/Urology |
| Primary Audience: | Oncologists; Hematologists; Pulmonologists; Urologists; Radiologists; Surgeons |
| Launch Date: | 11-May-10 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ |
| Expiration Date: | 10-May-11 |
Learning Objectives
Upon completion of the activity, participants should be able to:
- Identify the molecular alterations frequently seen in clear cell RCC in order to develop comprehensive treatment plans.
- Develop individualized treatment plans incorporating biologically targeted agents to improve survival outcomes in patients with RCC.
- Evaluate potential biomarkers predictive of response to antiangiogenic agents in RCC in order to improve patient outcomes.
Faculty
Ronald M. Bukowski, M.D.
Emeritus Staff & Consultant
Cleveland Clinic Taussig Cancer Center
Professor of Medicine
CCF Lerner College of Medicine of CWRU
Cleveland, Ohio
Daniel J. George, M.D.
Associate Professor of Medicine and Surgery
Divisions of Medical Oncology and Urology
Duke University Medical Center
Durham, North Carolina
Thomas E. Hutson, D.O., PharmD.
Director, Genitourinary Oncology Program
Baylor-Sammons Cancer Center
Baylor University Medical Center
Dallas, Texas
Emeritus Staff & Consultant
Cleveland Clinic Taussig Cancer Center
Professor of Medicine
CCF Lerner College of Medicine of CWRU
Cleveland, Ohio
Daniel J. George, M.D.Associate Professor of Medicine and Surgery
Divisions of Medical Oncology and Urology
Duke University Medical Center
Durham, North Carolina
Thomas E. Hutson, D.O., PharmD.Director, Genitourinary Oncology Program
Baylor-Sammons Cancer Center
Baylor University Medical Center
Dallas, Texas
Sponsorship Statement
Survival prognosis is related to extent of disease at diagnosis (Table 1). Most patients are diagnosed with localized disease (tumor confined to the primary site), and in this subgroup survival outcomes are quite favorable. However, for patients diagnosed with advanced or metastatic disease, long term survival prognosis remains poor.
How To Receive Credit
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Purdue University School of Pharmacy and balance ltd. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.Jointly sponsored by Purdue University School of Pharmacy and balance ltd.
Who Should Participate
This activity is designed for oncologists, hematologists, pulmonologists, urologists, radiologists, surgeons, and other health professionals interested in emerging approaches to managing patients with RCC.
Overview
Renal cell cancer (RCC) accounts for nearly 4% of all new cancer cases and 2% of cancer deaths in the United States. Estimates for 2008 project 54,390 new cases to be diagnosed and 13,010 RCC-related deaths.1 The median age at diagnosis is 65 years, with RCC occurring about twice as frequently in men compared to women.2 The incidence of RCC continues to rise at a rate of about 2% annually, though the mortality rate of RCC has trended downwards by 0.3% per year between 1992-2005.
The 5-year overall survival rate for RCC has gradually improved, from approximately 50% in the mid 1970s to a current rate of 66.5%.2 The rise in RCC incidence as well as the improved survival trend appears to be related to improved diagnostics, leading to more frequent incidental detection of RCCs and early identification of localized tumors.3
Survival prognosis is related to extent of disease at diagnosis (Table 1). Most patients are diagnosed with localized disease (tumor confined to the primary site), and in this subgroup survival outcomes are quite favorable. However, for patients diagnosed with advanced or metastatic disease, long term survival prognosis remains poor.
Though approximately 95% of RCCs occur sporadically, the relatively rare familial forms of RCC and their associated genetic abnormalities have provided great insight into the molecular pathways involved in RCC development.4, 5 Identification of these pathways has promoted the development of biologically targeted therapies in RCC.6
Table 1. Renal Cell Cancer - Relative Frequency and Survival Rates2
|
Disease at Diagnosis
|
Relative Frequency
|
5-year Relative Survival Rate
|
|
Localized
|
56%
|
90%
|
|
Regional
|
19%
|
61%
|
|
Distant
|
20%
|
10%
|
- American Cancer Society. Cancer Facts & Figures 2008. 2008:72. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed March 17, 2009.
- Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005, based on November 2007 SEER data submission, posted to the SEER web site, 2008. Bethesda, Maryland: National Cancer Institute;2008.
- Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. Sep 19 1996;335(12):865-875.
- Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. Dec 2003;170(6 Pt 1):2163-2172.
- Zbar B, Glenn G, Merino M, et al. Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol. Feb 2007;177(2):461-465; discussion 465.
- Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. Jan 15 2007;13(2 Pt 2):671s-679s.
How To Receive Credit
- Read the entire online virtual ground round.
- Complete the Activity Post-Test with a score of 70% or greater.
- Complete the Activity Evaluation.
- Then you may complete your certificate request form and submit.
- Your certificate may then be printed online.
Accreditation Statement
Credit Designation Statement
The Purdue University School of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.Faculty Disclosure Statement
All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University School of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, balance ltd., and Purdue University School of Pharmacy staff have no relationships to disclose.Dr. Bukowski has received grants, research support, honorarium and/or has consulted for Bayer Corporation; Genentech, Inc.; Novartis Corporation; Pfizer Inc.
Dr. George has received grants, research support, honorarium and/or has consulted for F. Hoffmann-La Roche Ltd; Genentech, Inc.; Molecular Insight; Novartis Corporation; Pfizer Inc.; sanofi-aventis U.S. LLC.
Dr. Hutson has received grants, research support, honorarium and/or has consulted for AVEO Pharmaceuticals, Inc.; Bayer Corporation; Genentech, Inc.; GlaxoSmithKline; Novartis Corporation; Pfizer Inc.; Wyeth.
Sponsorship Statement from Provider
Jointly sponsored by Purdue University School of Pharmacy and balance ltd.
Supporter Statement
Supported by an educational grant from Genentech, Inc.
Fee and Refund Statement
Free ProgramBy clicking below, you agree that you have read the program details and disclosures above.
